Vasoactive Intestinal Peptide Nanomedicine for the Management of Inflammatory Bowel Disease

Jayawardena, Dulari; Anbazhagan, Arivarasu Natarajan; Guzman, Grace; Dudeja, Pradeep K.; Önyüksel, Hayat

doi:10.1021/acs.molpharmaceut.7b00452

Cited by 32 publications

(24 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They characterized the healthy role of VIP and VIP-SSM in the DSS-induced colitis model. At clinical and histological levels, VIP and nanoparticles of VIP treatment decreased the pro-inflammatory cytokine profile in the colon, reducing tight junction and ion-transporter protein expression associated with severe DSS colitis [266].…”

Section: Inflammatory Bowel Diseasementioning

confidence: 94%

A Clinical Approach for the Use of VIP Axis in Inflammatory and Autoimmune Diseases

Martı́nez

Juarranz

Gutiérrez‐Cañas

et al. 2019

IJMS

View full text Add to dashboard Cite

The neuroendocrine and immune systems are coordinated to maintain the homeostasis of the organism, generating bidirectional communication through shared mediators and receptors. Vasoactive intestinal peptide (VIP) is the paradigm of an endogenous neuropeptide produced by neurons and endocrine and immune cells, involved in the control of both innate and adaptive immune responses. Exogenous administration of VIP exerts therapeutic effects in models of autoimmune/inflammatory diseases mediated by G-protein-coupled receptors (VPAC1 and VPAC2). Currently, there are no curative therapies for inflammatory and autoimmune diseases, and patients present complex diagnostic, therapeutic, and prognostic problems in daily clinical practice due to their heterogeneous nature. This review focuses on the biology of VIP and VIP receptor signaling, as well as its protective effects as an immunomodulatory factor. Recent progress in improving the stability, selectivity, and effectiveness of VIP/receptors analogues and new routes of administration are highlighted, as well as important advances in their use as biomarkers, contributing to their potential application in precision medicine. On the 50th anniversary of VIP’s discovery, this review presents a spectrum of potential clinical benefits applied to inflammatory and autoimmune diseases.

show abstract

Section: Inflammatory Bowel Diseasementioning

confidence: 94%

A Clinical Approach for the Use of VIP Axis in Inflammatory and Autoimmune Diseases

Martı́nez

Juarranz

Gutiérrez‐Cañas

et al. 2019

IJMS

View full text Add to dashboard Cite

show abstract

“…In humans, reduced levels of VPAC1 on immune cells as well as a reduced response to VIP stimulation were reported in ankylosing spondylitis, multiple sclerosis, RA and OA [ 81 , 162 , 163 , 164 ]. VIP-based therapies were especially effective in collagen-induced arthritis [ 105 , 165 ] and its therapeutic potential has been evaluated in a large number of experimental pathological conditions including inflammatory bowel disease [ 166 ], allergic asthma [ 167 ], wound healing [ 168 ] and stroke [ 169 ]. Scarce availability of the PACAP receptor 1 might indicate that the role of PACAP is less prominent or more specialized compared to the structurally related VIP.…”

Section: Effects Of the Neuroendocrine Systemmentioning

confidence: 99%

Do Neuroendocrine Peptides and Their Receptors Qualify as Novel Therapeutic Targets in Osteoarthritis?

Grässel

2018

IJMS

View full text Add to dashboard Cite

Joint tissues like synovium, articular cartilage, meniscus and subchondral bone, are targets for neuropeptides. Resident cells of these tissues express receptors for various neuroendocrine-derived peptides including proopiomelanocortin (POMC)-derived peptides, i.e., α-melanocyte-stimulating hormone (α-MSH), adrenocorticotropin (ACTH) and β-endorphin (β-ED), and sympathetic neuropeptides like vasoactive intestinal peptide (VIP) and neuropeptide y (NPY). Melanocortins attained particular attention due to their immunomodulatory and anti-inflammatory effects in several tissues and organs. In particular, α-MSH, ACTH and specific melanocortin-receptor (MCR) agonists appear to have promising anti-inflammatory actions demonstrated in animal models of experimentally induced arthritis and osteoarthritis (OA). Sympathetic neuropeptides have obtained increasing attention as they have crucial trophic effects that are critical for joint tissue and bone homeostasis. VIP and NPY are implicated in direct and indirect activation of several anabolic signaling pathways in bone and synovial cells. Additionally, pituitary adenylate cyclase-activating polypeptide (PACAP) proved to be chondroprotective and, thus, might be a novel target in OA. Taken together, it appears more and more likely that the anabolic effects of these neuroendocrine peptides or their respective receptor agonists/antagonists may be exploited for the treatment of patients with inflammatory and degenerative joint diseases in the future.

show abstract

“…Until now, the possibility to use VIP in the treatment of IBD is suggested by some investigations on experimentally induced intestinal diseases in rodents. Namely, it is known that the administration of VIP (especially using sterically stabilized micelles) is capable of alleviating colitis in mice and showing anti-inflammatory and antidiarrheal effects [ 49 ]. Therapeutic effects of VIP may result from VIP-induced stabilization of the intestinal immune homeostasis [ 50 ], protection of the epithelial mitochondria [ 51 ], roles in the maintenance of an appropriate intestinal barrier integrity [ 52 , 53 ] and blockage of the inflammatory cascade [ 54 ].…”

Section: Discussionmentioning

confidence: 99%

Vasoactive Intestinal Polypeptide (VIP) in the Intestinal Mucosal Nerve Fibers in Dogs with Inflammatory Bowel Disease

Rychlik

Gonkowski

Całka

et al. 2020

Animals

View full text Add to dashboard Cite

Canine inflammatory bowel disease (IBD) is a group of enteropathies with nonspecific chronic symptoms and poorly understood etiology. Many aspects connected with IBD are not understood. One of them is the participation of the intestinal nervous system in the development of pathological processes. Thus, this study aimed to demonstrate changes in the density of intramucosal nerve fibers containing vasoactive intestinal polypeptide (VIP)—one of the most important intestinal nervous factors caused by the various stages of IBD development. Mucosal biopsy specimens collected from the duodenum, jejunum and descending colon of healthy dogs and dogs with varied severity of IBD were included in the experiment. The density of VIP-like immunoreactive (VIP-LI) nerves was determined by a single immunofluorescence technique and a semi-quantitative method consisting in VIP-LI fiber counts in the field of view (0.1 mm2). The obtained results indicate that IBD induces changes in the density of mucosal VIP-LI nerve fibers in the canine gastrointestinal tract. The initial decrease is followed by an increase in VIP-like immunoreactivity in successive stages of the disease. These observations show that VIP is a neuronal factor that participates in the pathological processes connected with canine IBD. The observed changes probably result from the neuroprotective and/or adaptive properties of VIP. Protective and adaptive reactions induced by inflammation aim to protect the GI tract against damage by proinflammatory factors and ensure the homeostasis in the enteric nervous system (ENS) under the conditions changed by the disease process.

show abstract

Vasoactive Intestinal Peptide Nanomedicine for the Management of Inflammatory Bowel Disease

Cited by 32 publications

References 50 publications

A Clinical Approach for the Use of VIP Axis in Inflammatory and Autoimmune Diseases

A Clinical Approach for the Use of VIP Axis in Inflammatory and Autoimmune Diseases

Do Neuroendocrine Peptides and Their Receptors Qualify as Novel Therapeutic Targets in Osteoarthritis?

Vasoactive Intestinal Polypeptide (VIP) in the Intestinal Mucosal Nerve Fibers in Dogs with Inflammatory Bowel Disease

Contact Info

Product

Resources

About